Send to

Choose Destination
Biomark Med. 2019 Jun;13(9):761-771. doi: 10.2217/bmm-2018-0441. Epub 2019 Jun 3.

Expression of p16 and p53 in non-small-cell lung cancer: clinicopathological correlation and potential prognostic impact.

Author information

Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008, PR China.
Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA.
Department of Oncology, Sidney Kimmel Cancer Center at Johns Hopkins Medical Institutions, Baltimore, MD 21224, USA.
Department of Pathology, School of Basic Medical Science, Hangzhou Medical College, Hangzhou 310053, PR China.


Aim: p16 and p53 are frequently altered intracellular pathways in cancers. We investigated the aberrant expression of p16 and its relationship with p53 and HPV status in primary non-small-cell lung carcinoma. Patients & methods: Lung tumor tissue microarray (n = 163), immunohistochemical study of p16 and p53, and HPV in-situ hybridization were analyzed. Results: p16 and p53 were detected in 50.7 and 57.3% of adenocarcinoma (ADCs; n = 75), and 35.2 and 63.6% of squamous cell carcinoma (n = 88). HPV was detected in 16 and 10.2% of ADC and squamous cell carcinoma. In ADCs, p16 positive tumors demonstrated a favorable median overall survival time of 60.9 months, compared with p16 negative tumors of 46.9 months (p < 0.05). Furthermore, we did not find significant relationships between p16 expression and HPV status, nor with p53 expression. Conclusion: p16 play an unique role in lung cancer survival. The mechanism of p16 needs to be further studied.


hybridization; HPV; adenocarcinomas; biomarker; clinical survival; human papilloma virus; immunohistochemistry; non-small-cell lung carcinoma; p16; p53; squamous cell carcinomas


Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center